Atara Biotherap (ATRA)

$14.57 -2.29 (-13.58%)
Market Cap 128.13M
Revenue (ttm) 128.94M
Net Income (ttm) -85.40M
EPS (ttm) N/A
PE Ratio 8.30
Forward PE 20.79
Profit Margin -66.23%
Debt to Equity Ratio 0.00
Volume 227,600
Avg Vol 75,022
Day's Range N/A - N/A
Shares Out 7.21M
Stochastic %K 6%
Beta -0.41
Analysts Sell
Price Target $19.67

Company Profile

Atara Biotherapeutics, Inc. engages in the development of transformative therapies for patients with cancer and autoimmune disease in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) with post-transplant lymphoproliferative disease, as well as other EBV-driven diseases. The company has research collaboration agreements with Memorial Sloan Ket...

Industry: Biotechnology
Sector: Healthcare
Phone: 805 623 4211
Address:
1280 Rancho Conejo Blvd, Thousand Oaks, United States
Dragan7
Dragan7 Jan. 7 at 12:14 AM
$ATRA Will be halted tomorrow?
1 · Reply
UgoGreg
UgoGreg Jan. 6 at 10:54 PM
$ATRA https://youtu.be/7rkVJaCBKxQ
0 · Reply
Midori_Hachi
Midori_Hachi Jan. 6 at 9:37 PM
$ATRA
0 · Reply
Vakeshka
Vakeshka Jan. 6 at 8:54 PM
$ATRA looks like the market sees the reduction in milestone payment from 40 to 31 million as a negative...
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jan. 6 at 8:27 PM
$ATRA exactly
0 · Reply
diamond67
diamond67 Jan. 6 at 8:26 PM
$ATRA Why low volume and few watchers? Any leak of bad news?
0 · Reply
HamBoneXoXo
HamBoneXoXo Jan. 6 at 6:50 PM
$ATRA News says they let go of $9 million deferring to future sales. Generous when you are broke.
1 · Reply
Andadiser
Andadiser Jan. 6 at 4:37 PM
$ATRA if approuved , What is potential Price ?
1 · Reply
UgoGreg
UgoGreg Jan. 6 at 4:06 PM
$ATRA https://youtu.be/7rkVJaCBKxQ
0 · Reply
Wakaas93
Wakaas93 Jan. 6 at 2:48 PM
$ATRA Low volume dip Taken position
0 · Reply
Latest News on ATRA
Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

Nov 12, 2025, 9:00 AM EST - 7 weeks ago

Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress

Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Nov 3, 2025, 9:00 AM EST - 2 months ago

Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

Sep 29, 2025, 7:11 AM EDT - 3 months ago

4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals

ARWR ASMB CORT

Atara Biotherapeutics Announces Changes to Its Board of Directors

Sep 3, 2025, 6:00 PM EDT - 4 months ago

Atara Biotherapeutics Announces Changes to Its Board of Directors

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

Aug 11, 2025, 4:01 PM EDT - 5 months ago

Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Jul 24, 2025, 8:57 AM EDT - 5 months ago

Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD)

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Jul 24, 2025, 8:00 AM EDT - 5 months ago

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease

Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.

Jul 15, 2025, 8:00 AM EDT - 6 months ago

Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc.

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

Jul 14, 2025, 8:00 AM EDT - 6 months ago

Atara Biotherapeutics Provides Regulatory and Business Updates on Tabelecleucel (Tab-cel®)

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

May 16, 2025, 8:50 PM EDT - 8 months ago

Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

May 15, 2025, 8:35 AM EDT - 8 months ago

Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

Atara Biotherapeutics Announces Pricing of $16 Million Offering

May 15, 2025, 8:30 AM EDT - 8 months ago

Atara Biotherapeutics Announces Pricing of $16 Million Offering

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

May 5, 2025, 5:06 PM EDT - 8 months ago

Atara Biotherapeutics Provides Regulatory Updates on EBVALLO™ (tabelecleucel)

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

Mar 7, 2025, 4:01 PM EST - 10 months ago

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Operational Progress

The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Mar 1, 2025, 11:00 AM EST - 11 months ago

The Schall Law Firm Invites Investors With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Feb 15, 2025, 11:00 AM EST - 11 months ago

The Schall Law Firm Invites Shareholders With Losses In Atara Biotherapeutics, Inc. To Join A Securities Fraud Investigation

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

Feb 14, 2025, 8:11 AM EST - 11 months ago

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Atara Biotherapeutics, Inc. for potential violations of securities laws

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation

Feb 11, 2025, 7:00 AM EST - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Shareholders to Learn More About the Investigation

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Feb 10, 2025, 7:00 AM EST - 11 months ago

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation

Feb 9, 2025, 7:00 AM EST - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Shareholders to Inquire about Securities Investigation

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Feb 7, 2025, 4:01 PM EST - 11 months ago

Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect

Feb 7, 2025, 7:00 AM EST - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect

Feb 6, 2025, 7:00 AM EST - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Connect

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation

Feb 5, 2025, 7:00 AM EST - 11 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Stockholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation

Feb 4, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Investors to Learn More About the Investigation

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Atara Biotherapeutics, Inc. For Securities Fraud

Feb 3, 2025, 11:00 AM EST - 1 year ago

The Schall Law Firm Invites Shareholders With Losses To Join An Investigation Into Atara Biotherapeutics, Inc. For Securities Fraud

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 3, 2025, 7:00 AM EST - 1 year ago

Atara Biotherapeutics, Inc. (ATRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation

Jan 31, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Atara Biotherapeutics, Inc. (ATRA) and Encourages Stockholders to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation

Jan 30, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Encourages Atara Biotherapeutics, Inc. (ATRA) Investors to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out

Jan 29, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Investors to Reach Out

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Atara Biotherapeutics, Inc. For Securities Fraud

Jan 28, 2025, 11:00 AM EST - 1 year ago

The Schall Law Firm Urges Shareholders With Losses To Join An Inquiry Into Atara Biotherapeutics, Inc. For Securities Fraud

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out

Jan 28, 2025, 7:00 AM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Reach Out

ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Jan 28, 2025, 3:23 AM EST - 1 year ago

ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect

Jan 27, 2025, 8:30 PM EST - 1 year ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect

FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs

Jan 21, 2025, 1:11 PM EST - 1 year ago

FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

Jan 21, 2025, 7:30 AM EST - 1 year ago

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

Jan 21, 2025, 12:21 AM EST - 1 year ago

Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues

Dragan7
Dragan7 Jan. 7 at 12:14 AM
$ATRA Will be halted tomorrow?
1 · Reply
UgoGreg
UgoGreg Jan. 6 at 10:54 PM
$ATRA https://youtu.be/7rkVJaCBKxQ
0 · Reply
Midori_Hachi
Midori_Hachi Jan. 6 at 9:37 PM
$ATRA
0 · Reply
Vakeshka
Vakeshka Jan. 6 at 8:54 PM
$ATRA looks like the market sees the reduction in milestone payment from 40 to 31 million as a negative...
1 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jan. 6 at 8:27 PM
$ATRA exactly
0 · Reply
diamond67
diamond67 Jan. 6 at 8:26 PM
$ATRA Why low volume and few watchers? Any leak of bad news?
0 · Reply
HamBoneXoXo
HamBoneXoXo Jan. 6 at 6:50 PM
$ATRA News says they let go of $9 million deferring to future sales. Generous when you are broke.
1 · Reply
Andadiser
Andadiser Jan. 6 at 4:37 PM
$ATRA if approuved , What is potential Price ?
1 · Reply
UgoGreg
UgoGreg Jan. 6 at 4:06 PM
$ATRA https://youtu.be/7rkVJaCBKxQ
0 · Reply
Wakaas93
Wakaas93 Jan. 6 at 2:48 PM
$ATRA Low volume dip Taken position
0 · Reply
Dragan7
Dragan7 Jan. 6 at 2:46 PM
$ATRA Shorts will never roll over?
0 · Reply
Romeogattone
Romeogattone Jan. 6 at 11:15 AM
$ATRA https://www.ema.europa.eu/en/medicines/human/EPAR/ebvallo
0 · Reply
HamBoneXoXo
HamBoneXoXo Jan. 6 at 8:45 AM
$ATRA Jan 10, 2026 To Be or Not To Be
1 · Reply
takingstock73
takingstock73 Jan. 5 at 9:57 PM
$ATRA 4 Days and counting
0 · Reply
FITTEST_RETAIL_TRADER
FITTEST_RETAIL_TRADER Jan. 5 at 6:48 PM
$ATRA EARLY APPROVAL COMING
5 · Reply
FITTEST_RETAIL_TRADER
FITTEST_RETAIL_TRADER Jan. 5 at 6:40 PM
$ATRA
0 · Reply
Dragan7
Dragan7 Jan. 5 at 4:43 PM
$ATRA Atara Biotherapeutics Stock Forecast All Analysts Top Analysts Stock Price Forecast The 1 analyst with a 12-month price forecast for Atara Biotherapeutics stock has a target of 25, which predicts a 37.36% increase from the current stock price of 18.12. Price Target: $25 (+37.36%) Analyst Consensus: Buy https://stockanalysis.com/stocks/atra/forecast/
1 · Reply
DanyelFlag
DanyelFlag Jan. 5 at 1:57 PM
$ATRA back to $500? Possible?
0 · Reply
takingstock73
takingstock73 Jan. 5 at 1:03 PM
$ATRA let's run
0 · Reply
Smurfologist
Smurfologist Jan. 5 at 12:59 PM
$ATRA YEAH, BABY 🙏🏾💪🏾🐃💣💥🚀
0 · Reply
CharlieeMungerTWITS
CharlieeMungerTWITS Jan. 3 at 12:22 AM
$ATRA Atara does not benefit economically — but may benefit strategically. What Atara gains: • Preserves the partnership instead of risking a termination or dispute • Maintains a path to commercialization support • Possibly gains: • More flexibility on timing • Continued partner commitment during a fragile regulatory period What Atara gives up: • Lower future milestone payments • Reduced long-term upside if tab-cel succeeds • A signal to the market that their bargaining power is weakened This is best viewed as a concession, not a win.
0 · Reply
JohnTrack
JohnTrack Jan. 2 at 11:50 PM
$ATRA monitoring dips and rips!
0 · Reply